USA flag logo/image

An Official Website of the United States Government

An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75956
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AI063910
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANJIN GROUP, INC.
10 CHILHOWIE CT. COCKEYSVILLE, MD 21030 2202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: An IL-2 Receptor Targeted Toxin with Reduced VLS
Agency: HHS
Contract: 1R43AI063910-01
Award Amount: $144,786.00
 

Abstract:

DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusion protein toxin technology has not been widely developed due adverse events, especially vascular leak syndrome (VLS), associated with administration of these agents. The Anjin Group Inc [AGI] proposes to develop a third generation diphtheria toxin-based platform, modified to reduce VLS. Fusion protein toxins developed from such a toxophore may have broader clinical application due to an altered risk benefit profile for patients including those with non-life threatening disease.

Principal Investigator:

Johanna C. Vanderspek
4105611434
ANJIN_GROUP@EARTHLINK.NET

Business Contact:


5088316383
Small Business Information at Submission:

Anjin Group, Inc.
10 Chilhowie Ct. Cockeysville, MD 21030

EIN/Tax ID: 020669751
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No